advertisement
Abstract #3562 Published in IGR 4-2
Duration of therapy provided by bottle of ocular hypotensive eyedrops
Vaidergorn PG; Susanna Jr R; Borges AS; Giampani Jr JRevista Brasileira de Oftalmologia 2002; 61: 278-282
OBJECTIVE: To assess the mean extent of therapy yielded by bottle of some ocular hypotensive eyedrops: bimatoprost (Lumigan®, Allergan), latanoprost (Xalatan®, Pharmacia), travoprost (Travatan®, Alcon) and unoprostone (Rescula®, Novartis). SETTING: Glaucoma Service, Ophthalmology Department, Clinical Hospital, University of Sao Paulo Medical School. METHODS: The total drop contents of six bottles of each product were counted, so as to obtain a mean drop number. Mean number of drops per ml was calculated as well as the extent of time the therapeutics were enhanced by each product. RESULTS: The mean number of drops per ml was noted to vary across the group, as follows: Xalatan®, 43.4 ± 1.6, Travatan®, 38.7 ± 2.2, Rescula®, 37.6 ± 1.3, and Lumigan®, 34.9 ± 1.8 drops per ml. Regarding the mean treatment extent, assuming one drop per instillation, without waste, a bottle of Xalatan® lasted 54.2 ± 2.0 days, of Lumigan® 52.3 ± 2.7 days, of Rescula® 50.0 ± 1.7 days, and of Travatan® 48.4 ± 2.7 days. CONCLUSIONS: Among the items that might be considered when prescribing ocular hypotensive eyedrops, the number of drops, as well as the extent of therapeutics yielded per bottle could merit some attention. LA: Portuguese
Dr. P.G. Vaidergorn, Av. Dr. Eneas Carvalho Aguiar, 255, Sao Paulo, SP-CEP 05403-000, Brazil. pgelmann@yahoo.com.br
Classification:
11.1 General management, indication (Part of: 11 Medical treatment)
